Pre-COVID: the name of the game was digital transformation, agility, or optimization. Whilst all of those initiatives are still relevant and ongoing, the pandemic has forced many of us to focus on resilience through whatever forms of disruption we may encounter in the future. COVID-19 measures have changed the way we work and, regardless of whether these changes are temporary or a paradigm shift, we are presented with new challenges. Encouragingly, some of these new challenges have been addressed with innovative solutions to not only resolve the issues today but to also strengthen the overall infrastructure and response for tomorrow.
During this time, cybersecurity concerns have grown as a result of many factors, not least of which is a direct result from individuals being sentenced to work from home. From an industry perspective, companies are also more vulnerable to cybercrimes as they try to operate as much as possible remotely or face temporary or even permanent closures. Taking the valuable lessons learned during an exceptional time, what are the key steps to build a stronger, resilient system? Taking a step back, what are some key vulnerabilities companies should address?
In the last decade, the science of cell therapy and regenerative medicine has made remarkable progress. Work in this area has also resulted in numerous engineering successes, enabling sophisticated tools that open the door to new approaches for discovery and development of therapeutics. Particularly noteworthy is the recent progress in cell and molecular biology, including in stem cell research and gene editing. In this webinar, we will hear about new tools and the new directions they make possible as well as how each is being commercialized.
How can small molecules be identified that evoke cell or tissue regeneration by design? How can we engineer cells and tissue-growth in situ with a structure suitable for implantation? How can we physically gain access to the interior of cells for both discovery and engineering purposes? And how can the immune system be mapped with single-cell biology to accelerate discovery?